Teva Pharmaceutical Stock Forecast

Stock Price Forecast

The 13 analysts that cover Teva Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $41.27, which forecasts a 19.17% increase in the stock price over the next year. The lowest target is $33 and the highest is $50.

Price Target: $41.27 (+19.17%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$33	$41.27	$40	$50
Change	-4.71%	+19.17%	+15.51%	+44.38%

Analyst Ratings

The average analyst rating for Teva Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	8	8	8	8	8	8
Buy	4	4	4	4	5	5
Hold	0	0	1	1	0	0
Sell	1	1	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	13	13	13	13	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
David Amsellem Piper Sandler	Piper Sandler	Buy Reiterates $42	Buy	Reiterates	$42	+21.28%	Jun 1, 2026
Dennis Ding Jefferies	Jefferies	Buy Maintains $40	Buy	Maintains	$40	+15.51%	May 27, 2026
Glen Santangelo Barclays	Barclays	Buy Maintains $38 → $40	Buy	Maintains	$38 → $40	+15.51%	May 6, 2026
Salveen Richter Goldman Sachs	Goldman Sachs	Buy Maintains $45 → $50	Buy	Maintains	$45 → $50	+44.38%	Apr 30, 2026
Chris Schott J.P. Morgan	J.P. Morgan	Buy Maintains $35 → $40	Buy	Maintains	$35 → $40	+15.51%	Apr 30, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

16.65B

from 17.26B

-3.53%

from 17.26B

Revenue Next Year

17.26B

from 16.65B

3.67%

from 16.65B

EPS This Year

n/a

from -

EPS Next Year

n/a

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	15.88B	14.93B	15.85B	16.54B	17.26B	16.65B
Revenue Growth	-4.69%	-6.00%	6.17%	4.41%	4.32%	-3.53%
Gross Profit	7.59B	6.97B	7.65B	8.06B	8.94B	8.90B
Gross Margin	47.83%	46.72%	48.25%	48.74%	51.79%	53.48%
Operating Income	3.08B	2.66B	3.19B	3.37B	3.95B	4.21B
Net Income	417.00M	-2.45B	-559.00M	-1.64B	1.41B	1.74B
Free Cash Flow	2.31B	2.90B	3.30B	2.62B	2.03B	2.17B
No. Analysts	-	-	-	-	-	10

Revenue Forecast

Revenue	2026	2027	2028
High	17.4B
Avg	16.6B
Low	16.4B

Revenue Growth

Revenue Growth	2026	2027	2028
High	0.9%
Avg	-3.5%
Low	-4.8%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-
Low	-

EPS Growth

EPS Growth	2027	2028
High	-
Avg	-
Low	-